EMSP represented at DIA Europe meeting

EMSP’s Director of External Affairs Christoph Thalheim represented our organisation at the Drug Information Association’s (DIA) meeting of European health stakeholders, organised on 13 April in Paris, France.

Mr Thalheim was part of a panel discussion with representatives of DG Health, European Medicines Agency (EMA) and several NCAs (National Competent Authorities). His topic as leading panelist was: “Main patients’ benefits from 50 Years of EU pharma legislation”. The presentation was structured around four main headings:

• History of EPF as unique European voice of 150 million patients and EMSP’s role as co-founder
• Patient involvement in regulatory work – the example of EMSP – EMA collaboration
• Improvements achieved within the clinical trial regulation through active patient advocacy contributions
• Equal access to high standard healthcare in Europe – will the new cooperation between EMA and HTA be the pathway to end current inequalities?

Among the key benefits for EMSP’s presence at the DIA meeting, one stood out: increased visibility as example of good practice for active patient involvement and advocacy work in regulatory processes.